Gemcitabine and docetaxel combination for advanced soft tissue sarcoma

A nationwide retrospective study

Yunjung Choi, Mi Sun Yun, Sang Hee Lim, Jeeyun Lee, Jin Hee Ahn, Yu Jung Kim, Kyong Hwa Park, Young Suk Park, Ho Yeong Lim, Hyonggin An, Dong Churl Suh, Yeul Hong Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose This nationwide retrospective study was conducted to evaluate the efficacy and safety of combined gemcitabine and docetaxel (GD) as an off-label therapy for advanced soft tissue sarcoma, which has limited treatment options owing to its rare occurrence. Materials and Methods A total of 228 patients received GD therapy for advanced soft tissue sarcoma from 2009 to 2014 in Korea. We retrospectively reviewed the clinical medical records and claims data of these patients. Results A total of 218 patients in 20 medical centers were included in the final analysis (median age, 50.0 years). The objective response rate was 15.1% (34/218, in the leiomyosarcoma subgroup; 26.3%). The median overall survival and progression-free survival were 10.3 months (95% confidence interval [CI], 8.4 to 12.2) and 3.3 months (95% CI, 2.8 to 4.7), respectively. The treatment was discontinued in 7.8% of patients owing to adverse events; however, there was no adverse event-related death. Neutropenia (35.7%) and anemia (15.1%) were the most frequent grade 3/4 toxicities. Univariate analysis for identifying the predictors of the progression-free survival period revealed that patients aged ≤ 50 years had a hazard ratio of 1.388 (95% CI, 1.027 to 1.875; p < 0.05) relative to those aged > 50 years, and the group with leiomyosarcoma had a hazard ratio of 0.693 (95% CI, 0.493 to 0.975; p < 0.05) relative to the group with other histopathological subtypes. Conclusion GD therapy was tolerable and effective for Korean patients with soft tissue sarcoma. In conclusion, for patients with advanced soft tissue sarcoma, especially leiomyosarcoma, GD therapy could be an important therapeutic option.

Original languageEnglish
Pages (from-to)175-182
Number of pages8
JournalCancer Research and Treatment
Volume50
Issue number1
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

docetaxel
gemcitabine
Sarcoma
Retrospective Studies
Leiomyosarcoma
Confidence Intervals
Therapeutics
Disease-Free Survival
Korea
Neutropenia
Medical Records
Anemia

Keywords

  • Advanced soft tissue sarcoma
  • Docetaxel
  • Gemcitabine
  • Off-label use
  • Retrospective study

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gemcitabine and docetaxel combination for advanced soft tissue sarcoma : A nationwide retrospective study. / Choi, Yunjung; Yun, Mi Sun; Lim, Sang Hee; Lee, Jeeyun; Ahn, Jin Hee; Kim, Yu Jung; Park, Kyong Hwa; Park, Young Suk; Lim, Ho Yeong; An, Hyonggin; Suh, Dong Churl; Kim, Yeul Hong.

In: Cancer Research and Treatment, Vol. 50, No. 1, 01.01.2018, p. 175-182.

Research output: Contribution to journalArticle

Choi, Yunjung ; Yun, Mi Sun ; Lim, Sang Hee ; Lee, Jeeyun ; Ahn, Jin Hee ; Kim, Yu Jung ; Park, Kyong Hwa ; Park, Young Suk ; Lim, Ho Yeong ; An, Hyonggin ; Suh, Dong Churl ; Kim, Yeul Hong. / Gemcitabine and docetaxel combination for advanced soft tissue sarcoma : A nationwide retrospective study. In: Cancer Research and Treatment. 2018 ; Vol. 50, No. 1. pp. 175-182.
@article{9c07f7e69db54572aef3407ae9b7ffaf,
title = "Gemcitabine and docetaxel combination for advanced soft tissue sarcoma: A nationwide retrospective study",
abstract = "Purpose This nationwide retrospective study was conducted to evaluate the efficacy and safety of combined gemcitabine and docetaxel (GD) as an off-label therapy for advanced soft tissue sarcoma, which has limited treatment options owing to its rare occurrence. Materials and Methods A total of 228 patients received GD therapy for advanced soft tissue sarcoma from 2009 to 2014 in Korea. We retrospectively reviewed the clinical medical records and claims data of these patients. Results A total of 218 patients in 20 medical centers were included in the final analysis (median age, 50.0 years). The objective response rate was 15.1{\%} (34/218, in the leiomyosarcoma subgroup; 26.3{\%}). The median overall survival and progression-free survival were 10.3 months (95{\%} confidence interval [CI], 8.4 to 12.2) and 3.3 months (95{\%} CI, 2.8 to 4.7), respectively. The treatment was discontinued in 7.8{\%} of patients owing to adverse events; however, there was no adverse event-related death. Neutropenia (35.7{\%}) and anemia (15.1{\%}) were the most frequent grade 3/4 toxicities. Univariate analysis for identifying the predictors of the progression-free survival period revealed that patients aged ≤ 50 years had a hazard ratio of 1.388 (95{\%} CI, 1.027 to 1.875; p < 0.05) relative to those aged > 50 years, and the group with leiomyosarcoma had a hazard ratio of 0.693 (95{\%} CI, 0.493 to 0.975; p < 0.05) relative to the group with other histopathological subtypes. Conclusion GD therapy was tolerable and effective for Korean patients with soft tissue sarcoma. In conclusion, for patients with advanced soft tissue sarcoma, especially leiomyosarcoma, GD therapy could be an important therapeutic option.",
keywords = "Advanced soft tissue sarcoma, Docetaxel, Gemcitabine, Off-label use, Retrospective study",
author = "Yunjung Choi and Yun, {Mi Sun} and Lim, {Sang Hee} and Jeeyun Lee and Ahn, {Jin Hee} and Kim, {Yu Jung} and Park, {Kyong Hwa} and Park, {Young Suk} and Lim, {Ho Yeong} and Hyonggin An and Suh, {Dong Churl} and Kim, {Yeul Hong}",
year = "2018",
month = "1",
day = "1",
doi = "10.4143/crt.2016.535",
language = "English",
volume = "50",
pages = "175--182",
journal = "Cancer Research and Treatment",
issn = "1598-2998",
publisher = "Korean Society for Thoracic and Cardiovascular Surgery",
number = "1",

}

TY - JOUR

T1 - Gemcitabine and docetaxel combination for advanced soft tissue sarcoma

T2 - A nationwide retrospective study

AU - Choi, Yunjung

AU - Yun, Mi Sun

AU - Lim, Sang Hee

AU - Lee, Jeeyun

AU - Ahn, Jin Hee

AU - Kim, Yu Jung

AU - Park, Kyong Hwa

AU - Park, Young Suk

AU - Lim, Ho Yeong

AU - An, Hyonggin

AU - Suh, Dong Churl

AU - Kim, Yeul Hong

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Purpose This nationwide retrospective study was conducted to evaluate the efficacy and safety of combined gemcitabine and docetaxel (GD) as an off-label therapy for advanced soft tissue sarcoma, which has limited treatment options owing to its rare occurrence. Materials and Methods A total of 228 patients received GD therapy for advanced soft tissue sarcoma from 2009 to 2014 in Korea. We retrospectively reviewed the clinical medical records and claims data of these patients. Results A total of 218 patients in 20 medical centers were included in the final analysis (median age, 50.0 years). The objective response rate was 15.1% (34/218, in the leiomyosarcoma subgroup; 26.3%). The median overall survival and progression-free survival were 10.3 months (95% confidence interval [CI], 8.4 to 12.2) and 3.3 months (95% CI, 2.8 to 4.7), respectively. The treatment was discontinued in 7.8% of patients owing to adverse events; however, there was no adverse event-related death. Neutropenia (35.7%) and anemia (15.1%) were the most frequent grade 3/4 toxicities. Univariate analysis for identifying the predictors of the progression-free survival period revealed that patients aged ≤ 50 years had a hazard ratio of 1.388 (95% CI, 1.027 to 1.875; p < 0.05) relative to those aged > 50 years, and the group with leiomyosarcoma had a hazard ratio of 0.693 (95% CI, 0.493 to 0.975; p < 0.05) relative to the group with other histopathological subtypes. Conclusion GD therapy was tolerable and effective for Korean patients with soft tissue sarcoma. In conclusion, for patients with advanced soft tissue sarcoma, especially leiomyosarcoma, GD therapy could be an important therapeutic option.

AB - Purpose This nationwide retrospective study was conducted to evaluate the efficacy and safety of combined gemcitabine and docetaxel (GD) as an off-label therapy for advanced soft tissue sarcoma, which has limited treatment options owing to its rare occurrence. Materials and Methods A total of 228 patients received GD therapy for advanced soft tissue sarcoma from 2009 to 2014 in Korea. We retrospectively reviewed the clinical medical records and claims data of these patients. Results A total of 218 patients in 20 medical centers were included in the final analysis (median age, 50.0 years). The objective response rate was 15.1% (34/218, in the leiomyosarcoma subgroup; 26.3%). The median overall survival and progression-free survival were 10.3 months (95% confidence interval [CI], 8.4 to 12.2) and 3.3 months (95% CI, 2.8 to 4.7), respectively. The treatment was discontinued in 7.8% of patients owing to adverse events; however, there was no adverse event-related death. Neutropenia (35.7%) and anemia (15.1%) were the most frequent grade 3/4 toxicities. Univariate analysis for identifying the predictors of the progression-free survival period revealed that patients aged ≤ 50 years had a hazard ratio of 1.388 (95% CI, 1.027 to 1.875; p < 0.05) relative to those aged > 50 years, and the group with leiomyosarcoma had a hazard ratio of 0.693 (95% CI, 0.493 to 0.975; p < 0.05) relative to the group with other histopathological subtypes. Conclusion GD therapy was tolerable and effective for Korean patients with soft tissue sarcoma. In conclusion, for patients with advanced soft tissue sarcoma, especially leiomyosarcoma, GD therapy could be an important therapeutic option.

KW - Advanced soft tissue sarcoma

KW - Docetaxel

KW - Gemcitabine

KW - Off-label use

KW - Retrospective study

UR - http://www.scopus.com/inward/record.url?scp=85040457894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040457894&partnerID=8YFLogxK

U2 - 10.4143/crt.2016.535

DO - 10.4143/crt.2016.535

M3 - Article

VL - 50

SP - 175

EP - 182

JO - Cancer Research and Treatment

JF - Cancer Research and Treatment

SN - 1598-2998

IS - 1

ER -